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Background
A previous project called RARECARE (Surveillance of rare cancers 
in Europe) was an initiative to define and disseminate information 
about the burden of rare cancers in Europe. RARECARE revealed 
that rare cancers are not so rare. In Europe 500,000 rare cancers 
are newly diagnosed each year. Which means that 22% of all cancer 
cases are rare cancers. Due to their low frequency, rare cancers pose 
particular challenges such as late or incorrect diagnosis, less access to 
appropriate therapies, and absence of clinical trials. Overall a lower 
relative survival is found in patients diagnosed with a rare cancer. 
RARECARE Project turned into RARECAREnet which is a network of 
organisations collaborating in research and the identification of the 
appropriate solutions to address rare cancers difficulties. 
Objective
The RARECAREnet project aims at: 
t building an information network to provide comprehensive 
information on rare cancers to the community at large (oncologists, 
general practisioners, researchers, health authorities, patients)
t promoting international collaborative groups to foster research on 
rare cancers
t identifying determinants of variations in survival across Europe 




Main actions based on cancer registry data:
t Provision of updated incidence, prevalence and survival estimates 
for rare cancers, based on the EUROCARE database, including EU 
cancer registry data
t Create wide consensus with the major EU scientific societies and 
patient organisations on quality criteria for centres / networks of 
expertise for rare cancers
t High resolution studies on selected rare cancers (sarcomas, testicular 
cancer, head and neck cancer and GEP-NETs), to determine the health 
care pathway of these cancers
t Identification of centres of expertise for rare cancers in collaboration 
with patient organisations
Results
Quality criteria for centres / networks of expertise were developed 
in a multidisciplinary setting, resulting in indicators focusing on the 
three main pillars within the patient pathway: 
1. Diagnosis
 o Use of specific imaging
 o Stage at time of diagnose
 o Pathology report (reviewed)
 o Time between pathological confirmation and first treatment
2. Treatment
 o Referral pattern
 o Free margins after surgery / number of revisions
 o Time between first treatment and adjuvant therapy
3. Follow-up
 o Vital status of the patient
 o Cause of death
 o Last date of follow-up 
A high resolution study is put in place covering 4 national Cancer 
Registries and 11 regional Cancer Registries in Europe. 
Final results will be published at our website: www.rarecarenet.eu
In Europe
16,500,000
people live with cancer
4,300,000
with a rare cancer
PREVALENCE
24% of all people 
living with cancer 
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RARE CANCERS ARE NOT RARE
RARECAREnet supports rare cancers to be a political priority 
in the EU and EU member states, international collaboration 
to deal with the wide range of difficulties is essential. 
RARECAREnet (information network on rare cancers)
has received funding from the European Union, in the framework 
of the Health Programme.
COLLABORATING PARTNERS
t Rare Cancers Europe (RCE)
t European Society of Surgical Oncology (ESSO)
t European Society for Medical Oncology (ESMO)
t European Organisation for Research and Treatment of 
Cancer (EORTC)
t European School of Oncology (ESO)
t European Cancer Organisation (ECCO)
t Institut National de la Santé et de la Recherche 
Médicale (INSERM)-Orphanet
t Centro Léon Bérard, Lyon, France
t EUROPEAN CANCER REGISTRY BASED STUDY 
ON SURVIVAL AND CARE OF CANCER PATIENTS 
(EUROCARE)
t Leukemia Patient Advocates Foundation
t European Partnership for Action Angainst Cancer 
(EPAAC)
t Cancer52, UK
t European Society for Radiotherapy and Oncology 
(ESTRO)
ASSOCIATED PARTNERS
t Fondazione IRCCS, Istituto Nazionale  
dei Tumori, Milan, Italy
t The University of Edinburgh, Scotland, UK
t Institut de Cancérologie Gustave Roussy, France
t Istituto Superiore di Sanità, Italy
t Integraal Kankercentrum Nederland (IKNL)
t European Cancer Patient Coalition
t National Oncology Hospital, Bulgaria
t Cancer Society of Finland - Insitute  
for Statistical and Epidemiological Cancer 
Research, Finland
t Institute of Oncology Ljubljana, Slovenia
t National Cancer Registry Ireland
